{ "schemaVersion": 1, "organisationId": "O-694c87b4f94c47a0b4ba2a6245201a8f", "slug": "madrigal-pharmaceuticals-inc", "name": "MADRIGAL PHARMACEUTICALS, INC.", "updatedAt": "2026-10-02T12:55:27.443199Z", "sections": [ { "type": "OVERVIEW", "text": "Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. Its lead and sole marketed product is Rezdiffra (resmetirom), an oral, once-daily, liver-directed THR-β agonist and the first FDA-approved treatment for MASH. [P97859376] [P49845560]\n\nRezdiffra is approved in the United States and European Union for eligible adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis. Madrigal launched the product in the U.S. in April 2024 and in Germany in September 2025, and has described plans to expand into additional international markets. [P49845560]\n\nThe company reported $958.4 million in Rezdiffra net product revenue for 2025 and $675.6 million for the six months ended June 30, 2026. Its website describes its purpose as leading the fight against MASH and reports a workforce of hundreds across the U.S. and Europe. [P21555281] [T16561806] [https://www.madrigalpharma.com/about/]\n[P97859376][P49845560][P21555281][T16561806][https://www.madrigalpharma.com/about/][https://www.madrigalpharma.com/about/]", "updatedAt": "2026-10-02T12:55:27.443199Z" }, { "type": "PRODUCTS", "text": "Madrigal’s commercial product is Rezdiffra® (resmetirom), an oral, once-daily, liver-directed thyroid hormone receptor-β agonist. It is approved with diet and exercise for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis (F2–F3). The tablets are available in 60, 80, and 100 mg strengths, with recommended daily doses of 80 mg for patients weighing under 100 kg and 100 mg for those weighing 100 kg or more. Rezdiffra is also being studied for compensated MASH cirrhosis, an investigational use. [P144798888][P144798673][P144798910]\n\nThe pipeline includes MGL-2086, an oral small-molecule GLP-1 receptor agonist in Phase 1 testing, with a combination program with Rezdiffra planned; ervogastat, an oral DGAT-2 inhibitor in Phase 2; and MGL-0795, a GalNAc-conjugated siRNA targeting PNPLA3. Following Phase 1 proof-of-concept findings for MGL-0795, Madrigal said it would consult the FDA regarding a Phase 2 combination trial with resmetirom. The company also reports additional siRNA programs and preclinical MASH candidates. [P144565078][P144565080][P144565064][P144798842][P144798900][P144798889]\n\nRezdiffra is the only launched commercial product identified in the cited filings, and no separate service offering is reported. Net product revenue was $364.252 million in the second quarter of 2026 and $675.589 million in the first half of 2026; product revenue was the sole reported revenue line for those periods. [P49845560][P144798629]\n[P144798888][P144798673][P144798910][P144565078][P144565080][P144565064][P144798842][P144798900][P144798889][P49845560][P144798629][https://www.madrigalpharma.com/wp-content/uploads/2026/07/Combined-USPI_USPPI-July-2026.pdf][https://www.sec.gov/Archives/edgar/data/1157601/000162828026050845/mdgl-20260630.htm][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-second-quarter-2026-financial]", "updatedAt": "2026-10-02T12:55:27.443199Z" }, { "type": "GEOGRAPHY", "text": "Madrigal’s principal executive office is at 1001 Conshohocken State Road, Suite 2-350, West Conshohocken, Pennsylvania. The company also lists offices in Waltham, Massachusetts, and Baar, Switzerland, which it identifies as its international headquarters. [P144798576][https://www.madrigalpharma.com/contact-us/] Madrigal describes its workforce as based in the United States and Europe, but does not provide employee counts by location. [https://www.madrigalpharma.com/about/]\n\nIts documented commercial footprint includes the United States and Europe: Rezdiffra received European Commission conditional marketing authorization in August 2025, and Madrigal reported launching in Germany that September. The company has described a country-by-country EU launch, with availability dependent in part on national reimbursement procedures; authorization does not establish commercial availability in every EU country. [P11708594][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-european-commission-approval-rezdiffratm][https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/a3q25pressrelease.htm] The reviewed disclosures report consolidated revenue rather than a country or regional breakdown, so geographic revenue shares cannot be determined. [P21555281] Manufacturing is performed by third parties. [P60039325]\n[P144798576][https://www.madrigalpharma.com/contact-us/][https://www.madrigalpharma.com/about/][P11708594][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-european-commission-approval-rezdiffratm][https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/a3q25pressrelease.htm][P21555281][P60039325][https://www.madrigalpharma.com/contact-us/][https://www.madrigalpharma.com/about/][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-european-commission-approval-rezdiffratm][https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/a3q25pressrelease.htm]", "updatedAt": "2026-10-02T12:55:27.443199Z" }, { "type": "SEGMENTS", "text": "Madrigal Pharmaceuticals reports one operating/reportable segment; management does not divide its business for internal reporting or decision-making. The single segment is focused on developing and commercializing therapeutics for MASH, including Rezdiffra (resmetirom) [P107174999][P144798859][P144798659]. The company does not disclose a percentage contribution by multiple segments; with only one reported segment, a segment mix comparison is not applicable.\n[P107174999][P144798859][P144798659]", "updatedAt": "2026-10-02T12:55:27.443199Z" }, { "type": "HISTORY", "text": "Madrigal Pharmaceuticals traces its origins to Rebecca Taub, M.D.’s research into thyroid hormone receptor-β agonists; the company was incorporated in 2011. That year, Madrigal obtained rights and obligations under a Roche research and development agreement covering MGL-3196, later named resmetirom. [https://www.madrigalpharma.com/about/][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-company-founder-rebecca-taub][P188676631]\n\nIn July 2016, Madrigal completed a reverse merger with publicly traded Synta Pharmaceuticals. The combined company took the Madrigal name, and its shares began trading under the ticker MDGL. [P188677380][P188677359] The company advanced resmetirom through clinical development: it reported positive Phase 2 results in 2017–2018 and initiated a Phase 3 study in 2019. [P50324948][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-initiates-phase-3-multinational-double] In December 2022, it reported positive topline results from the pivotal MAESTRO-NASH trial. [https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3]\n\nIn September 2023, Bill Sibold became president and CEO, succeeding Paul Friedman. [P32368712][P61459315] The FDA granted accelerated approval to resmetirom, marketed as Rezdiffra, in March 2024, making it Madrigal’s first approved product; the company announced its U.S. availability the following month. [https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-us-availability-rezdiffratm] Rezdiffra received conditional marketing authorization from the European Commission in August 2025, followed by a Germany launch reported in September. [https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-european-commission-approval-rezdiffratm][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0]\n[https://www.madrigalpharma.com/about/][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-company-founder-rebecca-taub][P188676631][P188677380][P188677359][P50324948][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-initiates-phase-3-multinational-double][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3][P32368712][P61459315][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-us-availability-rezdiffratm][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-european-commission-approval-rezdiffratm][https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0]", "updatedAt": "2026-10-02T12:55:27.443199Z" } ], "sources": [ { "id": "P97859376", "href": "https://app.finbar.com/go?id=P97859376", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2025 Y)", "documentId": "D-9c16c7f1683b4f8cb076ef834b871e11" }, { "id": "P49845560", "href": "https://app.finbar.com/go?id=P49845560", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2025 Y)", "documentId": "D-9c16c7f1683b4f8cb076ef834b871e11" }, { "id": "P21555281", "href": "https://app.finbar.com/go?id=P21555281", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2025 Y)", "documentId": "D-9c16c7f1683b4f8cb076ef834b871e11" }, { "id": "T16561806", "href": "https://app.finbar.com/go?id=T16561806", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "https://www.madrigalpharma.com/about/", "href": "https://www.madrigalpharma.com/about/", "label": "www.madrigalpharma.com" }, { "id": "P144798888", "href": "https://app.finbar.com/go?id=P144798888", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "P144798673", "href": "https://app.finbar.com/go?id=P144798673", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "P144798910", "href": "https://app.finbar.com/go?id=P144798910", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "P144565078", "href": "https://app.finbar.com/go?id=P144565078", "label": "MADRIGAL PHARMACEUTICALS, INC. — Press release (2026 Q 2)", "documentId": "D-6eff701228974524b392a2beb6046ceb" }, { "id": "P144565080", "href": "https://app.finbar.com/go?id=P144565080", "label": "MADRIGAL PHARMACEUTICALS, INC. — Press release (2026 Q 2)", "documentId": "D-6eff701228974524b392a2beb6046ceb" }, { "id": "P144565064", "href": "https://app.finbar.com/go?id=P144565064", "label": "MADRIGAL PHARMACEUTICALS, INC. — Press release (2026 Q 2)", "documentId": "D-6eff701228974524b392a2beb6046ceb" }, { "id": "P144798842", "href": "https://app.finbar.com/go?id=P144798842", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "P144798900", "href": "https://app.finbar.com/go?id=P144798900", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "P144798889", "href": "https://app.finbar.com/go?id=P144798889", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "P144798629", "href": "https://app.finbar.com/go?id=P144798629", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "https://www.madrigalpharma.com/wp-content/uploads/2026/07/Combined-USPI_USPPI-July-2026.pdf", "href": "https://www.madrigalpharma.com/wp-content/uploads/2026/07/Combined-USPI_USPPI-July-2026.pdf", "label": "www.madrigalpharma.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1157601/000162828026050845/mdgl-20260630.htm", "href": "https://www.sec.gov/Archives/edgar/data/1157601/000162828026050845/mdgl-20260630.htm", "label": "www.sec.gov" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-second-quarter-2026-financial", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-second-quarter-2026-financial", "label": "ir.madrigalpharma.com" }, { "id": "P144798576", "href": "https://app.finbar.com/go?id=P144798576", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "https://www.madrigalpharma.com/contact-us/", "href": "https://www.madrigalpharma.com/contact-us/", "label": "www.madrigalpharma.com" }, { "id": "P11708594", "href": "https://app.finbar.com/go?id=P11708594", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2025 Y)", "documentId": "D-9c16c7f1683b4f8cb076ef834b871e11" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-european-commission-approval-rezdiffratm", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-european-commission-approval-rezdiffratm", "label": "ir.madrigalpharma.com" }, { "id": "https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/a3q25pressrelease.htm", "href": "https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/a3q25pressrelease.htm", "label": "www.sec.gov" }, { "id": "P60039325", "href": "https://app.finbar.com/go?id=P60039325", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2025 Y)", "documentId": "D-9c16c7f1683b4f8cb076ef834b871e11" }, { "id": "P107174999", "href": "https://app.finbar.com/go?id=P107174999", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2025 Y)", "documentId": "D-9c16c7f1683b4f8cb076ef834b871e11" }, { "id": "P144798859", "href": "https://app.finbar.com/go?id=P144798859", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "P144798659", "href": "https://app.finbar.com/go?id=P144798659", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2026 Q 2)", "documentId": "D-7f2933c2406b48609b33bb834f41c420" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-company-founder-rebecca-taub", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-company-founder-rebecca-taub", "label": "ir.madrigalpharma.com" }, { "id": "P188676631", "href": "https://app.finbar.com/go?id=P188676631", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2016 Y)", "documentId": "D-948d4dbdb2884686aba251e8ac264751" }, { "id": "P188677380", "href": "https://app.finbar.com/go?id=P188677380", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2016 Y)", "documentId": "D-948d4dbdb2884686aba251e8ac264751" }, { "id": "P188677359", "href": "https://app.finbar.com/go?id=P188677359", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2016 Y)", "documentId": "D-948d4dbdb2884686aba251e8ac264751" }, { "id": "P50324948", "href": "https://app.finbar.com/go?id=P50324948", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2023 Y)", "documentId": "D-e934f5212048496fa85ac87cdc9f7f51" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-initiates-phase-3-multinational-double", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-initiates-phase-3-multinational-double", "label": "ir.madrigalpharma.com" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3", "label": "ir.madrigalpharma.com" }, { "id": "P32368712", "href": "https://app.finbar.com/go?id=P32368712", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2023 Y)", "documentId": "D-e934f5212048496fa85ac87cdc9f7f51" }, { "id": "P61459315", "href": "https://app.finbar.com/go?id=P61459315", "label": "MADRIGAL PHARMACEUTICALS, INC. — Full financial report (2023 Y)", "documentId": "D-e934f5212048496fa85ac87cdc9f7f51" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm", "label": "ir.madrigalpharma.com" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-us-availability-rezdiffratm", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-announces-us-availability-rezdiffratm", "label": "ir.madrigalpharma.com" }, { "id": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0", "href": "https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-pharmaceuticals-reports-fourth-quarter-and-full-year-0", "label": "ir.madrigalpharma.com" } ] }